MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
0.3400
+0.0100
+3.03%
After Hours: 0.3321 -0.0079 -2.32% 19:36 05/15 EDT
OPEN
0.3300
PREV CLOSE
0.3300
HIGH
0.3400
LOW
0.3156
VOLUME
5.50M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.3142
MARKET CAP
79.80M
P/E (TTM)
-0.4561
1D
5D
1M
3M
1Y
5Y
1D
Gossamer Bio Q1 net loss widens to $46.66 million; revenue rises to $16.96 million
PUBT · 1d ago
Gossamer Bio: Q1 Earnings Snapshot
Barchart · 1d ago
Gossamer Bio to report first-quarter results, host conference call and webcast
PUBT · 1d ago
Press Release: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
Dow Jones · 1d ago
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 3d ago
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
PR Newswire · 4d ago
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 1, 2026 in Gossamer Bio, Inc. Lawsuit - GOSS
PR Newswire · 4d ago
Weekly Report: what happened at GOSS last week (0504-0508)?
Weekly Report · 5d ago
More
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.